{"title": "Vacunaci\u00f3n antigripal convencional frente a la vacuna de subunidades adyuvada con MF59", "author": "Mar\u00eda Amparo Torrecilla Rojas; Miguel Pedregal Gonz\u00e1lez; Ferm\u00edn Garc\u00eda Rodriguez; Josefa Ruiz Fern\u00e1ndez", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022087/", "hostname": "ncbi.nlm.nih.gov", "description": null, "sitename": "PubMed Central (PMC)", "date": "2009-12-22", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Learn more:\n[PMC Disclaimer](/pmc/about/disclaimer/)| [PMC Copyright Notice](/pmc/about/copyright/) [10.1016/j.aprim.2009.06.008](//doi.org/10.1016%2Fj.aprim.2009.06.008) [19800151](https://pubmed.ncbi.nlm.nih.gov/19800151)\nVacunaci\u00f3n antigripal convencional frente a la vacuna de subunidades adyuvada con MF59\nConventional influenza vaccination compared to MF59 adjuvanted subunit vaccine\nLas infecciones virales del tracto respiratorio imponen una carga de enfermedad alta a la sociedad, de ah\u00ed que desde la segunda mitad del siglo xx se hayan centrado los esfuerzos en la vacuna frente a la influenza para minimizar o prevenir su impacto\n[1](#bib1).\nPero la eficacia de las vacunas frente a la gripe no es siempre alta, lo que se debe no tanto a la propia vacuna, sino a los cambios antig\u00e9nicos frecuentes del virus\n[2](#bib2).\nPor todo esto, se siguen investigando diferentes formas de aumentar la inmunogenicidad de la vacuna, como el uso de adyuvantes, concretamente el MF59, en la vacuna de la gripe.\nEl adyuvante MF59\n[3](#bib3) es una emulsi\u00f3n de aceite en agua, que contiene escualeno, metabolito natural del colesterol que se encuentra en el ser humano como componente normal de las membranas celulares, y que de por s\u00ed no es inmun\u00f3geno, pero a\u00f1adido a algunas vacunas puede contribuir a aumentar la inmunogenicidad de \u00e9stas.\nActualmente disponemos de vacunas frente a la gripe de subunidades, virosomas, y fraccionada (las llamamos convencionales), y la nueva vacuna de subunidades adyuvada con MF59, desarrollada con el objetivo de aumentar la efectividad de las vacunas convencionales sin aumentar los efectos adversos.\nSin embargo, al revisar los estudios que comparan la vacuna adyuvada con las vacunas convencionales (\n[tabla 1](/pmc/articles/PMC7022087/table/tbl1/)) encontramos que:\n- \u2022Los ensayos cl\u00ednicos tienen problemas metodol\u00f3gicos.\n- \u2022Cuando se compara la eficacia inmunol\u00f3gica de la vacuna adyuvada frente a las vacunas convencionales, a los 28 d\u00edas tras la vacunaci\u00f3n, se obtienen resultados dispares sobre la eficacia, ya que mientras algunos estudios muestran resultados favorables a la vacuna adyuvada, como Baldo et al\n[4](#bib4), De Donato et al [5](#bib5)o Menegon et al [6](#bib6), otros muestran resultados favorables a las vacunas convencionales, como Squarcione et al [7](#bib7), Ruf et al [8](#bib8)o Bruijn et al [9](#bib9).\n- \u2022En los estudios de eficacia inmunol\u00f3gica a m\u00e1s largo plazo, a los 84, a los 180 o a los 360 d\u00edas tras la vacunaci\u00f3n, Pregliasco et al\n[10](#bib10)y Gabutti et al [11](#bib11)no reflejan superioridad inmunol\u00f3gica de la vacuna adyuvada frente a las vacunas convencionales. Incluso los que dieron resultados favorables a la vacuna adyuvada tras 28 d\u00edas, no muestran diferencias significativas entre ambos tipos de vacuna a los 180 y a los 360 d\u00edas, como Gasparini et al [12](#bib12)y Minutello et al [13](#bib13).\n- \u2022El estudio de efectividad cl\u00ednica de Iob et al\n[14](#bib14)compara la vacuna adyuvada con las vacunas convencionales, pero al no tener asignaci\u00f3n aleatorizada se invalidan en buena medida sus resultados y conclusiones. Los estudios de efectividad de Puig-Barber\u00e0 et al [15](#bib15), [16](#bib16)no tienen el dise\u00f1o adecuado para los objetivos que se proponen estudiar. Solamente mediante estimaciones de riesgo absoluto, reducci\u00f3n de riesgo absoluto y n\u00famero necesario a tratar es posible tomar decisiones cl\u00ednicas, y estos estudios no permiten calcularlas. Adem\u00e1s ambos trabajos est\u00e1n hechos frente a la no vacunaci\u00f3n.\n- \u2022En pacientes con VIH+, el estudio de Dorio et al\n[17](#bib17), sin asignaci\u00f3n aleatorizada y no ciego, compara la vacuna adyuvada con la de subunidades convencional, y a los 30 d\u00edas tras la vacunaci\u00f3n muestra incrementos del nivel de anticuerpos significativamente mayores para la vacuna adyuvada. Estos resultados contrastan con los presentados en el ensayo de Gabutti et al [15](#bib15), donde no se encuentra superioridad de la vacuna adyuvada frente a la de subunidades convencional, ni a los 28 ni a los 180 d\u00edas, tras la vacunaci\u00f3n.\n- \u2022Baldo et al\n[18](#bib18)comparan la inmunogenicidad y la seguridad de la vacuna adyuvada con la de subunidades convencional, en un ensayo aleatorizado, doble ciego, en adultos con enfermedades cr\u00f3nicas como c\u00e1ncer, diabetes mellitus, enfermedad card\u00edaca o enfermedad pulmonar, y obtienen en los vacunados con la vacuna adyuvada una significativa mayor respuesta de anticuerpos para la cepa A/H3N2 a las 4 semanas comparada con la vacuna convencional.\n- \u2022La mayor\u00eda de los ensayos cl\u00ednicos citados encuentran un significativo mayor n\u00famero de reacciones adversas, tanto locales como sist\u00e9micas, de la vacuna adyuvada frente a las vacunas convencionales, aunque ninguno fue grave.\n- \u2022\nTabla 1\n|Estudio||Vacunas incluidasa||Aleatorizado/ciego||n; poblaci\u00f3n||Tiempo (d\u00edas)||Resultados de inmunidad||Efectos adversos superiores a aSuV|\n|Baldo|[6](#bib6) [7](#bib7) [8](#bib8) [9](#bib9) [10](#bib10) [11](#bib11) [12](#bib12) [13](#bib13) [14](#bib14) [15](#bib15) [19](#bib19)\nNS: no significativo; VIH+: positivo para el virus de la inmunodeficiencia humana.\nEn resumen, la circulaci\u00f3n del virus de la gripe y sus modificaciones antig\u00e9nicas continuas contribuyen a la baja efectividad de las vacunas antigripales\n[1](#bib1), [2](#bib2). Es necesario seguir mejorando la efectividad de la vacunaci\u00f3n contra la gripe dado que, hasta la fecha, las evidencias no muestran una ventaja clara de la vacuna adyuvada frente a las vacunas convencionales.\nBibliograf\u00eda\n[PMC free article](/pmc/articles/PMC1626345/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/17068038)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=BMJ&title=Influenza+vaccination:+Policy+versus+evidence&author=T.+Jefferson&volume=333&publication_year=2006&pages=912-915&pmid=17068038&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/18939506)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nippon+Rinsho&title=Influenza+vaccine&author=T.+Horimoto&author=S.+Murakami&author=Y.+Kawaoka&volume=66&publication_year=2008&pages=2013-2018&pmid=18939506&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/17931147)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Vaccines&title=Vacuna+antigripal+de+subunidades+adyuvada+con+MF59:+una+vacuna+antigripal+interpand\u00e9mica+mejorada+para+poblaciones+vulnerables&author=J.+Puig-Barber\u00e0&author=D.+Gonz\u00e1lez+Vidal&volume=6&publication_year=2007&pages=659-665&pmid=17931147&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/11348713)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Comparison+of+three+different+influenza+vaccines+in+institutionalized+elderly&author=V.+Baldo&author=T.+Menegon&author=C.+Bonillo&author=A.+Florean&author=R.+Trivello&volume=19&publication_year=2001&pages=3472-3475&pmid=11348713&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/10462245)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Safety+and+immunogenicity+of+MF59-adjuvanted+influenza+vaccine+in+the+elderly&author=S.+De+Donato&author=D.+Granoff&author=M.+Minutillo&author=G.+Lecchi&author=M.+Faccini&volume=17&publication_year=1999&pages=3094-3101&pmid=10462245&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/10485352)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=European+J+Epidemiology&title=Influenza+vaccines:+Antibody+responses+to+split+virus+and+MF59-adjuvanted+subunit+virus+in+an+adult+population&author=T.+Menegon&author=V.+Baldo&author=C.+Bonillo&author=D.+Dalla+Costa&author=A.+Di+Tommaso&volume=15&publication_year=1999&pages=573-576&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/12559808)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Comparison+of+the+reactogenicity+and+immunogenicity+of+a+split+and+a+subunit-adjuvanted+influenza+vaccine+in+elderly+subjects&author=S.+Squarcione&author=S.+Sgricia&author=L.R.+Biasio&author=E.+Perinetti&volume=21&publication_year=2003&pages=1268-1274&pmid=12559808&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/15293073)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Infection&title=Open,+randomized+study+to+compare+the+immunogenicity+and+reactogenicity+of+an+influenza+split+vaccine+with+an+MF59-adjuvanted+subunit+vaccine+and+a+virosome-based+subunit+vaccine+in+elderly&author=B.R.+Ruf&author=K.+Colberg&author=M.+Frick&author=A.+Preusche&volume=32&publication_year=2004&pages=191-198&pmid=15293073&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/16901593)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=The+virisomal+influenza+vaccine+Invivac\u00ae:+Immunogenicity+and+tolerability+compared+to+an+adjuvanted+influenza+vaccine+(Fluad\u00ae)+in+elderly+subjects&author=I.A.+Bruijn&author=J.+Nauta&author=L.+Gerez&author=A.M.+Palache&volume=24&publication_year=2006&pages=6629-6631&pmid=16901593&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/11292151)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Aging+Clin+Exp+Res&title=Immunogenicity+and+safety+of+three+comercial+influenza+vaccines+in+institutionalized+elderly&author=F.+Pregliasco&author=C.+Mensi&author=W.+Serpilla&author=L.+Speccher&author=P.+Masella&volume=13&publication_year=2001&pages=38-43&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/16104444)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J+Int+Med+Res&title=Safety+and+immunogenicity+of+conventional+subunit+and+MF59-adjuvanted+influenza+vaccines+in+human+immunodeficiency+virus-1-seropositive+patients&author=G.+Gabutti&author=M.+Guido&author=P.+Durando&author=A.+De+Donno&author=M.+Quattrocchi&volume=33&publication_year=2005&pages=16-40&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/11599686)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur+J+Epidem&title=Increased+immunogenicity+of+the+MF59-adjuvanted+influenza+vaccine+compared+to+a+convencional+subunit+vaccine+in+elderly+subjects&author=R.+Gasparini&author=T.+Pozzi&author=E.+Montonoli&author=E.+Fragapane&author=F.+Senatore&volume=17&publication_year=2001&pages=135-140&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/9987141)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Safety+and+immunogenicity+of+an+inactivated+subunit+influenza+virus+vaccine+combined+with+MF59+adjuvant+emulsion+in+elderly+subjects,+immunized+for+three+consecutive+influenza+seasons&author=M.+Minutillo&author=F.+Senatore&author=G.+Cecchinelli&author=M.+Bianchi&author=T.+Andreani&volume=17&publication_year=1999&pages=99-104&pmid=9987141&)] [PMC free article](/pmc/articles/PMC2870297/)] [ [PubMed](https://pubmed.ncbi.nlm.nih.gov/16050515)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Epidemiol+Infect&title=Evidence+of+increased+clinical+protection+of+an+MF59-adjuvanted+influenza+vaccine+compared+to+a+non-adjuvant+vaccine+among+elderly+residents+of+long-term+care+facilities+in+Italy&author=A.+Iob&author=G.+Brianti&author=E.+Zamparo&author=T.+Gallo&volume=133&publication_year=2005&pages=687-693&pmid=16050515&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/15530669)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Effectiveness+of+the+MF59-adjuvanted+influenza+vaccine+in+preventing+emergency+admissions+for+pneumonia+in+the+elderly+over+64+years+of+age&author=J.+Puig-Barber\u00e0&author=J.+Diez-Domingo&author=S.+P\u00e9rez+Hoyos&author=A.+Berenguer+Varea&author=D.+Gonz\u00e1lez+Vidal&volume=23&publication_year=2004&pages=283-289&pmid=15530669&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/17889411)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Effectiveness+of+the+MF59-adjuvanted+influenza+vaccine+in+preventing+emergency+admissions+for+cardiovascular+disease,+cerebrovascular+disease+and+pneumonia+in+the+elderly&author=J.+Puig-Barber\u00e0&author=J.+Diez-Domingo&author=A.+Berenguer+Varea&author=G.+Schwarz+Chavarri&author=J.A.+Lluch+Rodrigo&volume=25&publication_year=2007&pages=7313-7321&pmid=17889411&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/12922092)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Antibody+responses+and+HIV-1+viral+load+in+HIV-1-seropositive+subjects+immunized+with+Esther+the+MF59-adjuvanted+influenza+vaccine+or+a+convencional+non-adjuvanted+subunit+vaccine+during+highly+active+antiretroviral+therapy&author=A.M.+Dorio&author=D.+Francisci&author=B.+Camilloni&author=G.+Stagni&author=M.+De+Martino&volume=21&publication_year=2003&pages=3629-3637&pmid=12922092&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/17383057)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=MF59-adjuvanted+influenza+vaccine+confers+superior+immunogenicity+in+adults+subjects+(18\u201360+years+of+age)+with+chronic+diseases+who+are+at+risk+of+post-influenza+complications&author=V.+Baldo&author=T.+Baldovin&author=A.+Floreani&author=A.F.+Carraro&author=R.+Trivello&volume=25&publication_year=2007&pages=3955-3961&pmid=17383057&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/16464520)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=An+MF59-adjuvanted+inactivated+influenza+vaccine+containing+A/Panama/1999+(H3N2)+induced+broader+serological+protection+against+heterovariant+influenza+virus+strain+A/Fujian/2002+than+a+subunit+and+a+split+influenza+vaccine&author=G.+Del+Giudice&author=A.K.+Hilbert&author=R.+Bugarini&author=A.+Minutillo&author=O.+Popota&volume=24&publication_year=2006&pages=3063-3065&pmid=16464520&)] [PubMed](https://pubmed.ncbi.nlm.nih.gov/18294741)] [ [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Cross-protection+by+MF59.adjuvanted+influenza+vaccine:+Neutralizing+and+hemagglutination.inhibiting+antibody+activity+against+A/H3N2+drifted+influenza+virases&author=F.+Ansaldi&author=S.+Bacilieri&author=P.+Durando&author=L.+Sticchi&author=L.+Valle&volume=26&publication_year=2008&pages=1525-1529&pmid=18294741&)]", "language": null, "image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0", "pagetype": "article", "links": ["#main-content", "https://www.ncbi.nlm.nih.gov/", "https://account.ncbi.nlm.nih.gov", "/myncbi/", "/myncbi/collections/bibliography/", "/account/settings/", "/account/signout/", "https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys", "https://www.ncbi.nlm.nih.gov", "/myncbi/", "#maincontent", "#", "/pmc/", "https://www.ncbi.nlm.nih.gov/pmc/advanced", "/pmc/about/userguide/", "/pmc/journals/", "/pmc/journals/3749/", "/pmc/issues/352491/", "/pmc/articles/PMC7022087/?report=reader", "/pmc/articles/PMC7022087/pdf/main.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7022087%2F&text=Vacunaci%F3n%20antigripal%20convencional%20frente%20a%20la%20vacuna%20de%20subunidades%20adyuvada%20con%20MF59", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7022087%2F", "/pmc/journals/", "/pmc/journals/3749/", "/pmc/issues/352491/", "/pmc/about/disclaimer/", "/pmc/about/copyright/", "//doi.org/10.1016%2Fj.aprim.2009.06.008", "https://pubmed.ncbi.nlm.nih.gov/19800151", "https://pubmed.ncbi.nlm.nih.gov/?term=Torrecilla%20Rojas%20MA%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Gonz\u00e1lez%20MP%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Garc\u00eda%20Rodriguez%20F%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Ruiz%20Fern\u00e1ndez%20J%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Torrecilla%20Rojas%20MA%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Gonz\u00e1lez%20MP%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Garc\u00eda%20Rodriguez%20F%5BAuthor%5D", "https://pubmed.ncbi.nlm.nih.gov/?term=Ruiz%20Fern\u00e1ndez%20J%5BAuthor%5D", "#", "#", "/pmc/about/disclaimer/", "mailto:dev@null", "mailto:dev@null", "/pmc/about/copyright/", "#bib1", "#bib2", "#bib3", "/pmc/articles/PMC7022087/table/tbl1/", "#bib4", "#bib5", "#bib6", "#bib7", "#bib8", "#bib9", "#bib10", "#bib11", "#bib12", "#bib13", "#bib14", "#bib15", "#bib16", "#bib17", "#bib15", "#bib18", "#bib19", "#bib20", "#bib5", "#bib6", "#bib7", "#bib8", "#bib9", "#bib10", "#bib11", "#bib12", "#bib13", "#bib14", "#bib15", "#bib19", "/pmc/articles/PMC7022087/table/tbl1/?report=objectonly", "#bib1", "#bib2", "/pmc/articles/PMC1626345/", "https://pubmed.ncbi.nlm.nih.gov/17068038", "https://scholar.google.com/scholar_lookup?journal=BMJ&title=Influenza+vaccination:+Policy+versus+evidence&author=T.+Jefferson&volume=333&publication_year=2006&pages=912-915&pmid=17068038&", "https://pubmed.ncbi.nlm.nih.gov/18939506", "https://scholar.google.com/scholar_lookup?journal=Nippon+Rinsho&title=Influenza+vaccine&author=T.+Horimoto&author=S.+Murakami&author=Y.+Kawaoka&volume=66&publication_year=2008&pages=2013-2018&pmid=18939506&", "https://pubmed.ncbi.nlm.nih.gov/17931147", "https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Vaccines&title=Vacuna+antigripal+de+subunidades+adyuvada+con+MF59:+una+vacuna+antigripal+interpand\u00e9mica+mejorada+para+poblaciones+vulnerables&author=J.+Puig-Barber\u00e0&author=D.+Gonz\u00e1lez+Vidal&volume=6&publication_year=2007&pages=659-665&pmid=17931147&", "https://pubmed.ncbi.nlm.nih.gov/11348713", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Comparison+of+three+different+influenza+vaccines+in+institutionalized+elderly&author=V.+Baldo&author=T.+Menegon&author=C.+Bonillo&author=A.+Florean&author=R.+Trivello&volume=19&publication_year=2001&pages=3472-3475&pmid=11348713&", "https://pubmed.ncbi.nlm.nih.gov/10462245", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Safety+and+immunogenicity+of+MF59-adjuvanted+influenza+vaccine+in+the+elderly&author=S.+De+Donato&author=D.+Granoff&author=M.+Minutillo&author=G.+Lecchi&author=M.+Faccini&volume=17&publication_year=1999&pages=3094-3101&pmid=10462245&", "https://pubmed.ncbi.nlm.nih.gov/10485352", "https://scholar.google.com/scholar_lookup?journal=European+J+Epidemiology&title=Influenza+vaccines:+Antibody+responses+to+split+virus+and+MF59-adjuvanted+subunit+virus+in+an+adult+population&author=T.+Menegon&author=V.+Baldo&author=C.+Bonillo&author=D.+Dalla+Costa&author=A.+Di+Tommaso&volume=15&publication_year=1999&pages=573-576&", "https://pubmed.ncbi.nlm.nih.gov/12559808", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Comparison+of+the+reactogenicity+and+immunogenicity+of+a+split+and+a+subunit-adjuvanted+influenza+vaccine+in+elderly+subjects&author=S.+Squarcione&author=S.+Sgricia&author=L.R.+Biasio&author=E.+Perinetti&volume=21&publication_year=2003&pages=1268-1274&pmid=12559808&", "https://pubmed.ncbi.nlm.nih.gov/15293073", "https://scholar.google.com/scholar_lookup?journal=Infection&title=Open,+randomized+study+to+compare+the+immunogenicity+and+reactogenicity+of+an+influenza+split+vaccine+with+an+MF59-adjuvanted+subunit+vaccine+and+a+virosome-based+subunit+vaccine+in+elderly&author=B.R.+Ruf&author=K.+Colberg&author=M.+Frick&author=A.+Preusche&volume=32&publication_year=2004&pages=191-198&pmid=15293073&", "https://pubmed.ncbi.nlm.nih.gov/16901593", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=The+virisomal+influenza+vaccine+Invivac\u00ae:+Immunogenicity+and+tolerability+compared+to+an+adjuvanted+influenza+vaccine+(Fluad\u00ae)+in+elderly+subjects&author=I.A.+Bruijn&author=J.+Nauta&author=L.+Gerez&author=A.M.+Palache&volume=24&publication_year=2006&pages=6629-6631&pmid=16901593&", "https://pubmed.ncbi.nlm.nih.gov/11292151", "https://scholar.google.com/scholar_lookup?journal=Aging+Clin+Exp+Res&title=Immunogenicity+and+safety+of+three+comercial+influenza+vaccines+in+institutionalized+elderly&author=F.+Pregliasco&author=C.+Mensi&author=W.+Serpilla&author=L.+Speccher&author=P.+Masella&volume=13&publication_year=2001&pages=38-43&", "https://pubmed.ncbi.nlm.nih.gov/16104444", "https://scholar.google.com/scholar_lookup?journal=J+Int+Med+Res&title=Safety+and+immunogenicity+of+conventional+subunit+and+MF59-adjuvanted+influenza+vaccines+in+human+immunodeficiency+virus-1-seropositive+patients&author=G.+Gabutti&author=M.+Guido&author=P.+Durando&author=A.+De+Donno&author=M.+Quattrocchi&volume=33&publication_year=2005&pages=16-40&", "https://pubmed.ncbi.nlm.nih.gov/11599686", "https://scholar.google.com/scholar_lookup?journal=Eur+J+Epidem&title=Increased+immunogenicity+of+the+MF59-adjuvanted+influenza+vaccine+compared+to+a+convencional+subunit+vaccine+in+elderly+subjects&author=R.+Gasparini&author=T.+Pozzi&author=E.+Montonoli&author=E.+Fragapane&author=F.+Senatore&volume=17&publication_year=2001&pages=135-140&", "https://pubmed.ncbi.nlm.nih.gov/9987141", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Safety+and+immunogenicity+of+an+inactivated+subunit+influenza+virus+vaccine+combined+with+MF59+adjuvant+emulsion+in+elderly+subjects,+immunized+for+three+consecutive+influenza+seasons&author=M.+Minutillo&author=F.+Senatore&author=G.+Cecchinelli&author=M.+Bianchi&author=T.+Andreani&volume=17&publication_year=1999&pages=99-104&pmid=9987141&", "/pmc/articles/PMC2870297/", "https://pubmed.ncbi.nlm.nih.gov/16050515", "https://scholar.google.com/scholar_lookup?journal=Epidemiol+Infect&title=Evidence+of+increased+clinical+protection+of+an+MF59-adjuvanted+influenza+vaccine+compared+to+a+non-adjuvant+vaccine+among+elderly+residents+of+long-term+care+facilities+in+Italy&author=A.+Iob&author=G.+Brianti&author=E.+Zamparo&author=T.+Gallo&volume=133&publication_year=2005&pages=687-693&pmid=16050515&", "https://pubmed.ncbi.nlm.nih.gov/15530669", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Effectiveness+of+the+MF59-adjuvanted+influenza+vaccine+in+preventing+emergency+admissions+for+pneumonia+in+the+elderly+over+64+years+of+age&author=J.+Puig-Barber\u00e0&author=J.+Diez-Domingo&author=S.+P\u00e9rez+Hoyos&author=A.+Berenguer+Varea&author=D.+Gonz\u00e1lez+Vidal&volume=23&publication_year=2004&pages=283-289&pmid=15530669&", "https://pubmed.ncbi.nlm.nih.gov/17889411", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Effectiveness+of+the+MF59-adjuvanted+influenza+vaccine+in+preventing+emergency+admissions+for+cardiovascular+disease,+cerebrovascular+disease+and+pneumonia+in+the+elderly&author=J.+Puig-Barber\u00e0&author=J.+Diez-Domingo&author=A.+Berenguer+Varea&author=G.+Schwarz+Chavarri&author=J.A.+Lluch+Rodrigo&volume=25&publication_year=2007&pages=7313-7321&pmid=17889411&", "https://pubmed.ncbi.nlm.nih.gov/12922092", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Antibody+responses+and+HIV-1+viral+load+in+HIV-1-seropositive+subjects+immunized+with+Esther+the+MF59-adjuvanted+influenza+vaccine+or+a+convencional+non-adjuvanted+subunit+vaccine+during+highly+active+antiretroviral+therapy&author=A.M.+Dorio&author=D.+Francisci&author=B.+Camilloni&author=G.+Stagni&author=M.+De+Martino&volume=21&publication_year=2003&pages=3629-3637&pmid=12922092&", "https://pubmed.ncbi.nlm.nih.gov/17383057", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=MF59-adjuvanted+influenza+vaccine+confers+superior+immunogenicity+in+adults+subjects+(18\u201360+years+of+age)+with+chronic+diseases+who+are+at+risk+of+post-influenza+complications&author=V.+Baldo&author=T.+Baldovin&author=A.+Floreani&author=A.F.+Carraro&author=R.+Trivello&volume=25&publication_year=2007&pages=3955-3961&pmid=17383057&", "https://pubmed.ncbi.nlm.nih.gov/16464520", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=An+MF59-adjuvanted+inactivated+influenza+vaccine+containing+A/Panama/1999+(H3N2)+induced+broader+serological+protection+against+heterovariant+influenza+virus+strain+A/Fujian/2002+than+a+subunit+and+a+split+influenza+vaccine&author=G.+Del+Giudice&author=A.K.+Hilbert&author=R.+Bugarini&author=A.+Minutillo&author=O.+Popota&volume=24&publication_year=2006&pages=3063-3065&pmid=16464520&", "https://pubmed.ncbi.nlm.nih.gov/18294741", "https://scholar.google.com/scholar_lookup?journal=Vaccine&title=Cross-protection+by+MF59.adjuvanted+influenza+vaccine:+Neutralizing+and+hemagglutination.inhibiting+antibody+activity+against+A/H3N2+drifted+influenza+virases&author=F.+Ansaldi&author=S.+Bacilieri&author=P.+Durando&author=L.+Sticchi&author=L.+Valle&volume=26&publication_year=2008&pages=1525-1529&pmid=18294741&", "/pmc/articles/PMC7022087/?report=reader", "/pmc/articles/PMC7022087/pdf/main.pdf", "#", "https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7022087%2F&text=Vacunaci%F3n%20antigripal%20convencional%20frente%20a%20la%20vacuna%20de%20subunidades%20adyuvada%20con%20MF59", "https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7022087%2F", "#", "https://twitter.com/ncbi", "https://www.facebook.com/ncbi.nlm", "https://www.linkedin.com/company/ncbinlm", "https://github.com/ncbi", "https://ncbiinsights.ncbi.nlm.nih.gov/", "https://www.nlm.nih.gov/socialmedia/index.html", "https://twitter.com/NLM_NIH", "https://www.facebook.com/nationallibraryofmedicine", "https://www.youtube.com/user/NLMNIH", "https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323", "https://www.nlm.nih.gov/web_policies.html", "https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office", "https://www.hhs.gov/vulnerability-disclosure-policy/index.html", "https://support.nlm.nih.gov/", "https://www.nlm.nih.gov/accessibility.html", "https://www.nlm.nih.gov/careers/careers.html", "//www.nlm.nih.gov/", "https://www.nih.gov/", "https://www.hhs.gov/", "https://www.usa.gov/"]}